Bavituximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | phosphatidylserine |
| Clinical data | |
| Routes of administration | infusion |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 30 hrs |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6446H9946N1702O2042S42 |
| Molar mass | 145304.87 g·mol−1 |
| (verify) | |
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.